The practical risk depends on several factors: which GLP-1 compound you take (semaglutide injection, oral semaglutide, tirzepatide, or microdose protocols), your current dose tier, individual variation in GI response, and whether your birth control contains standard or ultra-low hormone doses
Its gastrointestinal effects stem from slowed gastric emptying and altered gut motility, not from impaired enzyme production or secretion
What the Observational Evidence Actually Reports A retrospective cohort study published in The American Journal of Medicine used a global electronic health record database and, after propensity score matching, analysed 9,386 patients who had both systemic lupus erythematosus and type 2 diabetes, stratified by exposure to a GLP-1 receptor agonist
402, Santo Domingo, puedes llamar o escribir a 809-682-2151 ext